Onchocerciasis

Tropical Infectious Diseases

Volumn , Issue , 2011, Pages 741-749

  Hoerauf, Achim M ^a  

^a UNIVERSITY HOSPITAL BONN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84885150276     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-0-7020-3935-5.00106-3     Document Type: Chapter

References (143)

1. Henry NL, Law M, Nutman TB, et al. Onchocerciasis in a nonendemic population: clinical and immunologic assessment before treatment and at the time of presumed cure. J Infect Dis 2001, 183:512.
2. McCarthy JS, Ottesen EA, Nutman TB Onchocerciasis in endemic and nonendemic populations: differences in clinical presentation and immunologic findings. J Infect Dis 1994, 170:736.
3. Yameogo L, Toe L, Hougard JM, et al. Pool screen polymerase chain reaction for estimating the prevalence of Onchocerca volvulus infection in Simulium damnosum sensu lato: results of a field trial in an area subject to successful vector control. Am J Trop Med Hyg 1999, 60:124.
4. Taylor M, Hoerauf A Wolbachia bacteria of filarial nematodes. Parasitol Today 1999, 15:437.
5. Hoerauf A, Volkmann L, Hamelmann C, et al. Endosymbiotic bacteria in worms as targets for a novel chemotherapy in filariasis. Lancet 2000, 355:1242.
6. Hoerauf A, Mand S, Adjei O, et al. Depletion of Wolbachia endobacteria in Onchocerca volvulus by doxycycline and microfilaridermia after ivermectin treatment. Lancet 2001, 357:1415.
7. Hoerauf A, Büttner DW, Adjei O, et al. Clinical review - onchocerciasis. Endosymbiotic Wolbachia bacteria in the worms are targets for a new therapeutic approach. Br Med J 2003, 326:207.
8. Hoerauf A, Mand S, Volkmann L, et al. Doxycycline in the treatment of human onchocerciasis: kinetics of Wolbachia endobacteria reduction and of inhibition of embryogenesis in female Onchocerca worms. Microbes Infect 2003, 5:261.
9. Hoerauf A, Specht S, Buttner M, et al. Wolbachia endobacteria depletion by doxycycline as antifilarial therapy has macrofilaricidal activity in onchocerciasis: a randomized placebo-controlled study. Med Microbiol Immunol 2008, 197:295.
10. Nelson GS Human onchocerciasis: notes on the history, the parasite and the life cycle. Ann Trop Med Parasitol 1991, 85:83.
11. Robles R A new disease from Guatemala. Juventud Med Guatemala 1917, 15:97.
12. Kluxen G, Hoerauf A The significance of some observations on African ocular onchocerciasis described by Jean Hissette (1888-1965). Bull Soc Belge Ophtalmol 2008, 53.
13. Duke BO Human onchocerciasis - an overview of the disease. Acta Leiden 1990, 59:9.
14. Duke BOL The population dynamics of Onchocerca volvulus in the human host. Trop Med Parasitol 1993, 44:61.
15. Tang J, Toe L, Back C, et al. The Simulium damnosum species complex: phylogenetic analysis and molecular identification based upon mitochondrially encoded gene sequences. Insect Mol Biol 1995, 4:79.
16. Toe L, Tang J, Back C, et al. Vector-parasite transmission complexes for onchocerciasis in West Africa. Lancet 1997, 349:163.
17. Ndyomugyenyi R, Tukesiga E, Buttner DW, et al. The impact of ivermectin treatment alone and when in parallel with Simulium neavei elimination on onchocerciasis in Uganda. Trop Med Int Health 2004, 9:882.
18. Garms R, Lakwo TL, Ndyomugyenyi R, et al. The elimination of the vector Simulium neavei from the Itwara onchocerciasis focus in Uganda by ground larviciding. Acta Trop 2009, 111:203.
19. Rodriguez-Perez MA, Danis-Lozano R, Rodriguez MH, et al. Detection of Onchocerca volvulus infection in Simulium ochraceum sensu lato: comparison of a PCR assay and fly dissection in a Mexican hypoendemic community. Parasitology 1999, 119:613.
20. Basanez MG, Pion SD, Churcher TS, et al. River blindness: a success story under threat?. PLoS Med 2006, 3:e371.
21. WHO. Onchocerciasis and its control. WHO Tech Rep Ser 1995, 852:1.
22. Remme JH Research for control: the onchocerciasis experience. Trop Med Int Health 2004, 9:243.
23. Flockhart HA, Cibulskis RE, Karam M, et al. Onchocerca volvulus: enzyme polymorphism in relation to the differentiation of forest and savannah strains of this parasite. Trans R Soc Trop Med Hyg 1986, 80:285.
24. Lobos E, Weiss N Immunochemical comparison between worm extracts of Onchocerca volvulus from savanna and rain forest. Parasite Immunol 1985, 7:333.
25. Erttmann KD, Meredith SE, Greene BM, et al. Isolation and characterization of form specific DNA sequences of O. volvulus. Acta Leiden 1990, 59:253.
26. Meredith SE, Lando G, Gbakima AA, et al. Onchocerca volvulus: application of the polymerase chain reaction to identification and strain differentiation of the parasite. Exp Parasitol 1991, 73:335.
27. Zimmerman PA, Dadzie KY, De Sole G, et al. Onchocerca volvulus DNA probe classification correlates with epidemiologic patterns of blindness. J Infect Dis 1992, 165:964.
28. Higazi TB, Katholi CR, Mahmoud BM, et al. Onchocerca volvulus: genetic diversity of parasite isolates from Sudan. Exp Parasitol 2001, 97:24.
29. Ogunrinade A, Boakye D, Merriweather A, et al. Distribution of the blinding and nonblinding strains of Onchocerca volvulus in Nigeria. J Infect Dis 1999, 179:1577.
30. Dadzie KY, Remme J, Rolland A, et al. Ocular onchocerciasis and intensity of infection in the community. II. West African rainforest foci of the vector Simulium yahense. Trop Med Parasitol 1989, 40:348.
31. Remme J, Dadzie KY, Rolland A, et al. Ocular onchocerciasis and intensity of infection in the community. I. West African savanna. Trop Med Parasitol 1989, 40:340.
32. Little MP, Basanez MG, Breitling LP, et al. Incidence of blindness during the Onchocerciasis control programme in western Africa, 1971-2002. J Infect Dis 2004, 189:1932.
33. Kirch AK, Duerr HP, Boatin B, et al. Impact of parental onchocerciasis and intensity of transmission on development and persistence of Onchocerca volvulus infection in offspring: an 18 year follow-up study. Parasitology 2003, 127:327.
34. Murdoch ME, Asuzu MC, Hagan M, et al. Onchocerciasis: the clinical and epidemiological burden of skin disease in Africa. Ann Trop Med Parasitol 2002, 96:283.
35. Murdoch ME, Hay RJ, Mackenzie CD, et al. A clinical classification and grading system of the cutaneous changes in onchocerciasis. Br J Dermatol 1993, 129:260.
36. Kabore JK, Cabore JW, Melaku Z, et al. Epilepsy in a focus of onchocerciasis in Burkina Faso. Lancet 1996, 347:836.
37. Kipp W, Kasoro S, Burnham G Onchocerciasis and epilepsy in Uganda. Lancet 1994, 343:183.
38. Newell ED, Vyungimana F, Bradley JE Epilepsy, retarded growth and onchocerciasis, in two areas of different endemicity of onchocerciasis in Burundi. Trans R Soc Trop Med Hyg 1997, 91:525.
39. Duke BO Onchocerciasis, epilepsy and hyposexual dwarfism. Trans R Soc Trop Med Hyg 1998, 92:236.
40. Druet-Cabanac M, Boussinesq M, Dongmo L, et al. Review of epidemiological studies searching for a relationship between onchocerciasis and epilepsy. Neuroepidemiology 2004, 23:144.
41. Twum-Danso NA Mass treatment of onchocerciasis with ivermectin: should people with epilepsy and/or growth-retardation syndromes be excluded?. Ann Trop Med Parasitol 2004, 98:99.
42. Winkler AS, Friedrich K, Konig R, et al. The head nodding syndrome - clinical classification and possible causes. Epilepsia 2008, 49:2008.
43. Kirkwood B, Smith P, Marshall T, et al. Relationships between mortality, visual acuity and microfilarial load in the area of the Onchocerciasis Control Programme. Trans R Soc Trop Med Hyg 1983, 77:862.
44. Little MP, Breitling LP, Basanez MG, et al. Association between microfilarial load and excess mortality in onchocerciasis: an epidemiological study. Lancet 2004, 363:1514.
45. Lipner EM, Law MA, Barnett E, et al. Filariasis in travelers presenting to the GeoSentinel Surveillance Network. PLoS Negl Trop Dis 2007, 1:e88.
46. Kipp W, Bamhuhiiga J Onchodermal skin disease in a hyperendemic onchocerciasis focus in western Uganda. Am J Trop Med Hyg 2002, 67:475.
47. Tawill SA, Gallin M, Erttmann KD, et al. Impaired antibody responses and loss of reactivity to Onchocerca volvulus antigens by HIV-seropositive onchocerciasis patients. Trans R Soc Trop Med Hyg 1996, 90:85.
48. Fischer P, Kipp W, Kabwa P, et al. Onchocerciasis and human immunodeficiency virus in western Uganda: prevalences and treatment with ivermectin. Am J Trop Med Hyg 1995, 53:171.
49. Hoerauf A, Brattig N Resistance and susceptibility in human onchocerciasis - beyond Th1 vs. Th2. Trends Parasitol 2002, 18:25.
50. Gallin M, Edmonds K, Ellner JJ, et al. Cell-mediated immune response in human infection with Onchocerca volvulus. J Immunol 1988, 140:1999.
51. Ward DJ, Nutman TB, Zea-Flores G, et al. Onchocerciasis and immunity in humans: enhanced T-cell responsiveness to parasite antigen in putatively immune individuals. J Infect Dis 1988, 157:536.
52. Soboslay PT, Luder CG, Riesch S, et al. Regulatory effects of Th1-type (IFN-gamma, IL-12) and Th2-type cytokines (IL-10, IL-13) on parasite-specific cellular responsiveness in Onchocerca volvulus-infected humans and exposed endemic controls. Immunology 1999, 97:219.
53. Doetze A, Satoguina J, Burchard G, et al. Antigen-specific cellular hyporesponsiveness in generalized onchocerciasis is mediated by Th3/Tr1-type cytokines IL-10 and TGF-beta but not by a Th1 to Th2 shift. Int Immunol 2000, 12:623.
54. Semnani RT, Sabzevari H, Iyer R, et al. Filarial antigens impair the function of human dendritic cells during differentiation. Infect Immun 2001, 69:5813.
55. Schonemeyer A, Lucius R, Sonnenburg B, et al. Modulation of human T cell responses and macrophage functions by onchocystatin, a secreted protein of the filarial nematode Onchocerca volvulus. J Immunol 2001, 167:3207.
56. Schnoeller C, Rausch S, Pillai S, et al. A helminth immunomodulator reduces allergic and inflammatory responses by induction of IL-10-producing macrophages. J Immunol 2008, 180:4265.
57. Kilian HD, Nielsen G Cell-mediated and humoral immune responses to BCG and rubella vaccinations and to recall antigens in onchocerciasis patients. Trop Med Parasitol 1989, 40:445.
58. Kilian HD, Nielsen G Cell-mediated and humoral immune response to tetanus vaccinations in onchocerciasis patients. Trop Med Parasitol 1989, 40:285.
59. Soboslay PT, Dreweck CM, Hoffmann WH, et al. Ivermectin-facilitated immunity in onchocerciasis. Reversal of lymphocytopenia, cellular anergy and deficient cytokine production after single treatment. Clin Exp Immunol 1992, 89:407.
60. Soboslay PT, Lüder CG, Hoffmann WH, et al. Ivermectin-facilitated immunity in onchocerciasis; activation of parasite-specific Th1-type responses with subclinical Onchocerca volvulus infection. Clin Exp Immunol 1994, 96:238.
61. Soboslay PT, Geiger SM, Weiss N, et al. The diverse expression of immunity in humans at distinct states of Onchocerca volvulus infection. Immunology 1997, 90:592.
62. Allen JE, Adjei O, Bain O, et al. Of mice, cattle, and humans: the immunology and treatment of river blindness. PLoS Negl Trop Dis 2008, 2:e217.
63. + regulatory T cells and granzyme expression. Microbes Infect 2008, 10:313.
64. Satoguina J, Mempel M, Larbi J, et al. Antigen-specific T regulatory-1 cells are associated with immunosuppression in a chronic helminth infection (onchocerciasis). Microbes Infect 2002, 4:1291.
65. Hoerauf A, Kaifi J, Büttner DW TGF-beta and suppression of Th2-mediated hyperreactivity in a chronic human helminth infection (onchocerciasis). Am J Trop Med Hyg 2003, 69(suppl.):566.
66. Brattig NW, Schwohl A, Hoerauf A, et al. Identification of the lipid mediator prostaglandin E2 in tissue immune cells of humans infected with the filaria Onchocerca volvulus. Acta Trop 2009, 112:231.
67. Hoerauf A, Kruse S, Brattig NW, et al. The variant Arg110Gln of human IL-13 is associated with an immunologically hyper-reactive form of onchocerciasis (sowda). Microbes Infect 2002, 4:37.
68. Turaga PS, Tierney TJ, Bennett KE, et al. Immunity to onchocerciasis: cells from putatively immune individuals produce enhanced levels of interleukin-5, gamma interferon, and granulocyte-macrophage colony-stimulating factor in response to Onchocerca volvulus larval and male worm antigens. Infect Immun 2000, 68:1905.
69. Duerr HP, Dietz K, Schulz-Key H, et al. Density-dependent parasite establishment suggests infection-associated immunosuppression as an important mechanism for parasite density regulation in onchocerciasis. Trans R Soc Trop Med Hyg 2003, 97:242.
70. Schulz-Key H, Soboslay PT Parasitological and epidemiological aspects of the host-parasite interaction in filariases and their relevance for intervention and control. Nova Acta Leopoldina 2000, 313:189.
71. Keiser PB, Reynolds SM, Awadzi K, et al. Bacterial endosymbionts of Onchocerca volvulus in the pathogenesis of posttreatment reactions. J Infect Dis 2002, 185:805.
72. Mazzotti L The feasibility of using the allergic reactions which follow the administration of hetrazan as an auxiliary means of diagnosis in onchocerciasis. Rev Inst Salud Enfermed Trop Mex 1948, 9:935.
73. Brattig NW, Bazzocchi C, Kirschning CJ, et al. The major surface protein of Wolbachia endosymbionts in filarial nematodes elicits immune responses through TLR2 and TLR4. J Immunol 2004, 173:437.
74. Hise AG, Daehnel K, Gillette-Ferguson I, et al. Innate immune responses to endosymbiotic Wolbachia bacteria in Brugia malayi and Onchocerca volvulus are dependent on TLR2, TLR6, MyD88, and Mal, but not TLR4, TRIF, or TRAM. J Immunol 2007, 178:1068.
75. Turner JD, Langley RS, Johnston KL, et al. Wolbachia lipoprotein stimulates innate and adaptive immunity through toll-like receptors 2 and 6 (TLR2/6) to induce disease manifestations of filariasis. J Biol Chem 2009.
76. Saint Andre A, Blackwell NM, Hall LR, et al. The role of endosymbiotic Wolbachia bacteria in the pathogenesis of river blindness. Science 2002, 295:1892.
77. Taylor HR, Munoz B, Keyvan-Larijani E, et al. Reliability of detection of microfilariae in skin snips in the diagnosis of onchocerciasis. Am J Trop Med Hyg 1989, 41:467.
78. Buck AA, Anderson RI, Colston JA, et al. Microfilaruria in onchocerciasis. A clinical and epidemiological follow-up study in the Republic of Chad. Bull WHO 1971, 45:353.
79. Leichsenring M, Troger J, Nelle M, et al. Ultrasonographical investigations of onchocerciasis in Liberia. Am J Trop Med Hyg 1990, 43:380.
80. Francis H, Awadzi K, Ottesen EA The Mazzotti reaction following treatment of onchocerciasis with diethylcarbamazine: clinical severity as a function of infection intensity. Am J Trop Med Hyg 1985, 34:529.
81. Taylor HR Mazzotti test for onchocerciasis. Lancet 1992, 339:1549.
82. Kilian HD The use of a topical Mazzotti test in the diagnosis of onchocerciasis. Trop Med Parasitol 1988, 39:235.
83. Toe L, Adjami AG, Boatin BA, et al. Topical application of diethylcarbamazine to detect onchocerciasis recrudescence in west Africa. Trans R Soc Trop Med Hyg 2000, 94:519.
84. Boatin BA, Toe L, Alley ES, et al. Detection of Onchocerca volvulus infection in low prevalence areas: a comparison of three diagnostic methods. Parasitology 2002, 125:545.
85. Toe L, Boatin BA, Adjami A, et al. Detection of Onchocerca volvulus infection by O-150 polymerase chain reaction analysis of skin scratches. J Infect Dis 1998, 178:282.
86. Pischke S, Buttner DW, Liebau E, et al. An internal control for the detection of Onchocerca volvulus DNA by PCR-ELISA and rapid detection of specific PCR products by DNA detection test strips. Trop Med Int Health 2002, 7:526.
87. Plaisier AP, van Oortmarssen GJ, Remme J, et al. The reproductive lifespan of Onchocerca volvulus in West African savanna. Acta Trop 1991, 48:271.
88. Campbell WC Ivermectin as an antiparasitic agent for use in humans. Annu Rev Microbiol 1991, 45:445.
89. Cully DF, Vassilatis DK, Liu KK, et al. Cloning of an avermectin-sensitive glutamate-gated chloride channel from Caenorhabditis elegans. Nature 1994, 371:707.
90. Greene BM, Taylor HR, Cupp EW, et al. Comparison of ivermectin and diethylcarbamazine in the treatment of onchocerciasis. N Engl J Med 1985, 313:133.
91. Greene BM, Dukuly ZD, Munoz B, et al. A comparison of 6-, 12-, and 24-monthly dosing with ivermectin for treatment of onchocerciasis. J Infect Dis 1991, 163:376.
92. Brieger WR, Awedoba AK, Eneanya CI, et al. The effects of ivermectin on onchocercal skin disease and severe itching: results of a multicentre trial. Trop Med Int Health 1998, 3:951.
93. Emukah EC, Osuoha E, Miri ES, et al. A longitudinal study of impact of repeated mass ivermectin treatment on clinical manifestations of onchocerciasis in Imo State, Nigeria. Am J Trop Med Hyg 2004, 70:556.
94. Molyneux DH, Bradley M, Hoerauf A, et al. Mass drug treatment for lymphatic filariasis and onchocerciasis. Trends Parasitol 2003, 19:516.
95. Tielsch JM, Beeche A Impact of ivermectin on illness and disability associated with onchocerciasis. Trop Med Int Health 2004, 9:A45.
96. Awadzi K, Attah SK, Addy ET, et al. The effects of high-dose ivermectin regimens on Onchocerca volvulus in onchocerciasis patients. Trans R Soc Trop Med Hyg 1999, 93:189.
97. Gardon J, Boussinesq M, Kamgno J, et al. Effects of standard and high doses of ivermectin on adult worms of Onchocerca volvulus: a randomised controlled trial. Lancet 2002, 360:203.
98. Kamgno J, Gardon J, Gardon-Wendel N, et al. Adverse systemic reactions to treatment of onchocerciasis with ivermectin at normal and high doses given annually or three-monthly. Trans R Soc Trop Med Hyg 2004, 98:496.
99. Awadzi K, Addy ET, Opoku NO, et al. The chemotherapy of onchocerciasis XX: ivermectin in combination with albendazole. Trop Med Parasitol 1995, 46:213.
100. Bryan RT, Stokes SL, Spencer HC Expatriates treated with ivermectin. Lancet 1991, 337:304.
101. Davidson RN, Godfrey-Faussett P, Bryceson AD Adverse reactions in expatriates treated with ivermectin. Lancet 1990, 336:1005.
102. Whitworth JA, Maude GH, Luty AJ Expatriates treated with ivermectin. Lancet 1991, 337:625.
103. Hoerauf A Filariasis: new drugs and new opportunities for lymphatic filariasis and onchocerciasis. Curr Opin Infect Dis 2008, 21:673.
104. Chijioke CP, Okonkwo PO Adverse events following mass ivermectin therapy for onchocerciasis. Trans R Soc Trop Med Hyg 1992, 86:284.
105. Pacque M, Munoz B, Greene BM, et al. Community-based treatment of onchocerciasis with ivermectin: safety, efficacy, and acceptability of yearly treatment. J Infect Dis 1991, 163:381.
106. Awadzi K Clinical picture and outcome of serious adverse events in the treatment of onchocerciasis. Filaria J 2003, 2(suppl 1):S6.
107. Pacque M, Munoz B, Poetschke G, et al. Pregnancy outcome after inadvertent ivermectin treatment during community-based distribution. Lancet 1990, 336:1486.
108. Twum-Danso NA, Meredith SE Variation in incidence of serious adverse events after onchocerciasis treatment with ivermectin in areas of Cameroon co-endemic for loiasis. Trop Med Int Health 2003, 8:820.
109. Twum-Danso NA Serious adverse events following treatment with ivermectin for onchocerciasis control: a review of reported cases. Filaria J 2003, 2(suppl 1):S3.
110. Twum-Danso NA Loa loa encephalopathy temporally related to ivermectin administration reported from onchocerciasis mass treatment programs from 1989 to 2001: implications for the future. Filaria J 2003, 2(suppl 1):S7.
111. Awadzi K, Attah SK, Addy ET, et al. Thirty-month follow-up of sub-optimal responders to multiple treatments with ivermectin, in two onchocerciasis-endemic foci in Ghana. Ann Trop Med Parasitol 2004, 98:359.
112. Awadzi K, Boakye DA, Edwards G, et al. An investigation of persistent microfilaridermias despite multiple treatments with ivermectin, in two onchocerciasis-endemic foci in Ghana. Ann Trop Med Parasitol 2004, 98:231.
113. Osei-Atweneboana MY, Eng JK, Boakye DA, et al. Prevalence and intensity of Onchocerca volvulus infection and efficacy of ivermectin in endemic communities in Ghana: a two-phase epidemiological study. Lancet 2007, 369:2021.
114. Ardelli BF, Prichard RK Identification of variant ABC-transporter genes among Onchocerca volvulus collected from ivermectin-treated and untreated patients in Ghana, West Africa. Ann Trop Med Parasitol 2004, 98:371.
115. Bourguinat C, Pion SD, Kamgno J, et al. Genetic selection of low fertile Onchocerca volvulus by ivermectin treatment. PLoS Negl Trop Dis 2007, 1:e72.
116. Kuesel A Reviving Research in Liberia 2009, 82. World Health Organization, TDR news, Geneva.
117. Hoerauf A, Marfo-Debrekyei Y, Büttner M, et al. Efficacy of five weeks doxycycline treatment on adult Onchocerca volvulus. Parasitol Res 2009, 104:437.
118. Awadzi K, Hero M, Opoku NO, et al. The chemotherapy of onchocerciasis XVIII. Aspects of treatment with suramin. Trop Med Parasitol 1995, 46:19.
119. Chijioke CP, Umeh RE, Mbah AU, et al. Clinical pharmacokinetics of suramin in patients with onchocerciasis. Eur J Clin Pharmacol 1998, 54:249.
120. Duke BO Suramin and the time it takes to kill Onchocerca volvulus. Trop Med Parasitol 1991, 42:346.
121. Casiraghi M, McCall JW, Simoncini L, et al. Tetracycline treatment and sex-ratio distortion: a role for Wolbachia in the moulting of filarial nematodes?. Int J Parasitol 2002, 32:1457.
122. Hoerauf A, Nissen-Pähle K, Schmetz C, et al. Tetracycline therapy targets intracellular bacteria in the filarial nematode Litomosoides sigmodontis and results in filarial infertility. J Clin Invest 1999, 103:11.
123. Smith HL, Rajan TV Tetracycline inhibits development of the infective-stage larvae of filarial nematodes in vitro. Exp Parasitol 2000, 95:265.
124. Rao RU, Moussa H, Weil GJ Brugia malayi: effects of antibacterial agents on larval viability and development in vitro. Exp Parasitol 2002, 101:77.
125. Arumugam S, Pfarr KM, Hoerauf A Infection of the intermediate mite host with Wolbachia-depleted Litomosoides sigmodontis microfilariae: impaired L1 to L3 development and subsequent sex-ratio distortion in adult worms. Int J Parasitol 2008, 38:981.
126. Abraham D, Lucius R, Trees AJ Immunity to Onchocerca spp. in animal hosts. Trends Parasitol 2002, 18:164.
127. Lange AM, Yutanawiboonchai W, Scott P, et al. IL-4 and IL-5-dependent protective immunity to Onchocerca volvulus infective larvae in BALB/cBYJ mice. J Immunol 1994, 153:205.
128. Lustigman S, James ER, Tawe W, et al. Towards a recombinant antigen vaccine against Onchocerca volvulus. Trends Parasitol 2002, 18:135.
129. Tchakoute VL, Graham SP, Jensen SA, et al. In a bovine model of onchocerciasis, protective immunity exists naturally, is absent in drug-cured hosts, and is induced by vaccination. Proc Natl Acad Sci USA 2006, 103:5971.
130. Nutman TB Future directions for vaccine-related onchocerciasis research. Trends Parasitol 2002, 18:237.
131. Thylefors B Eliminating onchocerciasis as a public health problem. Trop Med Int Health 2004, 9:A1.
132. Boatin BA, Richards FO Control of onchocerciasis. Adv Parasitol 2006, 61:349.
133. Peters DH, Phillips T Mectizan Donation Program: evaluation of a public-private partnership. Trop Med Int Health 2004, 9:A4.
134. WHO. African Programme for Onchocerciasis Control - Report on Task Force Meeting, July 2008 2008, 83. World Health Organization, Geneva, Weekly Epidemiological Report.
135. Borsboom GJ, Boatin BA, Nagelkerke NJ, et al. Impact of ivermectin on onchocerciasis transmission: assessing the empirical evidence that repeated ivermectin mass treatments may lead to elimination/eradication in West-Africa. Filaria J 2003, 2:8.
136. Dadzie Y, Neira M, Hopkins D Final report of the Conference on the Eradicability of Onchocerciasis. Filaria J 2003, 2:2.
137. Diawara L, Traore MO, Badji A, et al. Feasibility of onchocerciasis elimination with ivermectin treatment in endemic foci in Africa: first evidence from studies in Mali and Senegal. PLoS Negl Trop Dis 2009, 3:e497.
138. Addiss DG, Rheingans R, Twum-Danso NA, et al. A Framework for decision-making for mass distribution of Mectizan(R) in areas endemic for Loa loa. Filaria J 2003, 2(suppl 1):S9.
139. Diggle PJ, Thomson MC, Christensen OF, et al. Spatial modelling and the prediction of Loa loa risk: decision making under uncertainty. Ann Trop Med Parasitol 2007, 101:499.
140. Taylor MJ, Awadzi K, Basanez MG, et al. Onchocerciasis Control: vision for the future from a Ghanian perspective. Parasit Vectors 2009, 2:7.
141. WHO. Report from the Inter-American Conference on Onchocerciasis, Quito, Ecuador, November 2007. Geneva: Weekly Epidemiological Report 2008;83:256.
142. Gonzalez RJ, Cruz-Ortiz N, Rizzo N, et al. Successful interruption of transmission of Onchocerca volvulus in the Escuintla-Guatemala focus, Guatemala. PLoS Negl Trop Dis 2009, 3(e404).
143. Lindblade KA, Arana B, Zea-Flores G, et al. Elimination of Onchocerca volvulus transmission in the Santa Rosa focus of Guatemala. Am J Trop Med Hyg 2007, 77:334.